liquid biopsy prevents inaccurate her2 status determination by in situ hybridization in a patient with invasive ductal adenocarcinoma of the breast: case report

Clicks: 173
ID: 204699
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Utilization of circulating tumor DNA as a novel and noninvasive test for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In the wake of FDA approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical utility of liquid biopsy for cancer management throughout the course of the disease. This case report describes a female with invasive ductal adenocarcinoma of the breast, where liquid biopsy was instrumental for her cancer characterization and personalized therapy selection.
Reference Key
tzeng2017caseliquid Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Yen-Dun Tony  Tzeng;Shih-En Chang;Rui Mei;Manana  Javey
Journal multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015
Year 2017
DOI
10.1159/000480698
URL
http://www.karger.com/Article/FullText/480698
Keywords
Breast cancer her2 liquid biopsy Oncology personalized therapy including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.